Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 166

Similar articles for PubMed (Select 23075019)

1.

A Bayesian approach for PK/PD modeling with PD data below limit of quantification.

Zhou H, Hartford A, Tsai K.

J Biopharm Stat. 2012;22(6):1220-43. doi: 10.1080/10543406.2011.585441.

PMID:
23075019
2.
3.
4.

Errors-in-variables in joint population pharmacokinetic/pharmacodynamic modeling.

Bennett J, Wakefield J.

Biometrics. 2001 Sep;57(3):803-12.

PMID:
11550931
5.

Application of the Bayesian dynamic survival model in medicine.

He J, McGee DL, Niu X.

Stat Med. 2010 Feb 10;29(3):347-60. doi: 10.1002/sim.3795.

PMID:
20014356
6.

Evaluations of Bayesian and maximum likelihood methods in PK models with below-quantification-limit data.

Yang S, Roger J.

Pharm Stat. 2010 Oct-Dec;9(4):313-30. doi: 10.1002/pst.400. Erratum in: Pharm Stat. 2011 Mar-Apr;10(2):187-9.

PMID:
20043295
7.

Bayesian population approaches to the analysis of dose escalation studies.

Russu A, De Nicolao G, Poggesi I, Neve M, Gomeni R.

Comput Methods Programs Biomed. 2012 Aug;107(2):189-201. doi: 10.1016/j.cmpb.2011.05.010. Epub 2011 Jul 20.

PMID:
21764475
8.

Simultaneous versus sequential pharmacokinetic-pharmacodynamic population analysis using an iterative two-stage Bayesian technique.

Proost JH, Schiere S, Eleveld DJ, Wierda JM.

Biopharm Drug Dispos. 2007 Nov;28(8):455-73.

PMID:
17847121
9.

Bayesian analysis of population PK/PD models: general concepts and software.

Lunn DJ, Best N, Thomas A, Wakefield J, Spiegelhalter D.

J Pharmacokinet Pharmacodyn. 2002 Jun;29(3):271-307.

PMID:
12449499
10.

Data cloning: easy maximum likelihood estimation for complex ecological models using Bayesian Markov chain Monte Carlo methods.

Lele SR, Dennis B, Lutscher F.

Ecol Lett. 2007 Jul;10(7):551-63. Erratum in: Ecol Lett. 2007 Sep;10(9):866.

PMID:
17542934
11.

Simultaneous vs. sequential analysis for population PK/PD data II: robustness of methods.

Zhang L, Beal SL, Sheinerz LB.

J Pharmacokinet Pharmacodyn. 2003 Dec;30(6):405-16.

PMID:
15000422
12.

Use of Bayesian Markov Chain Monte Carlo methods to model cost-of-illness data.

Cooper NJ, Sutton AJ, Mugford M, Abrams KR.

Med Decis Making. 2003 Jan-Feb;23(1):38-53.

PMID:
12583454
13.

Bayesian nonparametric population models: formulation and comparison with likelihood approaches.

Wakefield J, Walker S.

J Pharmacokinet Biopharm. 1997 Apr;25(2):235-53.

PMID:
9408861
14.

The application of a Bayesian approach to the analysis of a complex, mechanistically based model.

Jonsson F, Jonsson EN, Bois FY, Marshall S.

J Biopharm Stat. 2007;17(1):65-92.

PMID:
17219756
15.

Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses.

Keizer RJ, Jansen RS, Rosing H, Thijssen B, Beijnen JH, Schellens JH, Huitema AD.

Pharmacol Res Perspect. 2015 Mar;3(2):e00131. doi: 10.1002/prp2.131. Epub 2015 Mar 25.

16.

A Bayesian population PK-PD model of ispinesib-induced myelosuppression.

Kathman SJ, Williams DH, Hodge JP, Dar M.

Clin Pharmacol Ther. 2007 Jan;81(1):88-94.

PMID:
17186004
17.

Markov chain Monte Carlo: an introduction for epidemiologists.

Hamra G, MacLehose R, Richardson D.

Int J Epidemiol. 2013 Apr;42(2):627-34. doi: 10.1093/ije/dyt043.

18.

Use of Bayesian methods for multivariate bioequivalence measures.

Molina de Souza R, Achcar JA, Martinez EZ.

J Biopharm Stat. 2009;19(1):42-66. doi: 10.1080/10543400802513676.

PMID:
19127466
19.

Combining MCMC with 'sequential' PKPD modelling.

Lunn D, Best N, Spiegelhalter D, Graham G, Neuenschwander B.

J Pharmacokinet Pharmacodyn. 2009 Feb;36(1):19-38. doi: 10.1007/s10928-008-9109-1. Epub 2009 Jan 9.

PMID:
19132515
20.

Bayesian internal dosimetry calculations using Markov Chain Monte Carlo.

Miller G, Martz HF, Little TT, Guilmette R.

Radiat Prot Dosimetry. 2002;98(2):191-8.

PMID:
11926369
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk